Compare KPTI & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | FRD |
|---|---|---|
| Founded | 2008 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.0M | 146.2M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | FRD |
|---|---|---|
| Price | $9.40 | $18.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 604.4K | 20.1K |
| Earning Date | 02-12-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | N/A | ★ 172.86 |
| EPS | N/A | ★ 2.22 |
| Revenue | $146,067,000.00 | ★ $584,350,000.00 |
| Revenue This Year | $3.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.72 |
| Revenue Growth | 0.57 | ★ 30.55 |
| 52 Week Low | $3.51 | $12.24 |
| 52 Week High | $10.38 | $24.37 |
| Indicator | KPTI | FRD |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 41.25 |
| Support Level | $5.90 | $19.38 |
| Resistance Level | $9.94 | $24.37 |
| Average True Range (ATR) | 0.92 | 1.18 |
| MACD | 0.32 | -0.05 |
| Stochastic Oscillator | 87.50 | 9.80 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.